Prestige Consumer Healthcare (NYSE:PBH) Full Year 2025 Results

Key Financial Results

• Revenue: US$1.14b (up 1.1% from FY 2024).
• Net income: US$214.6m (up 2.5% from FY 2024).
• Profit margin: 19% (in line with FY 2024).
• EPS: US$4.32 (up from US$4.21 in FY 2024).

We've discovered 1 warning sign about Prestige Consumer Healthcare. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Prestige Consumer Healthcare EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.2%.

The primary driver behind last 12 months revenue was the North American Over-The-Counter (OTC) Healthcare segment contributing a total revenue of US$963.9m (85% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$155.7m (36% of total expenses). Explore how PBH's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

The company's shares are up 4.9% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Prestige Consumer Healthcare has 1 warning sign we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.